Jeff Lamken, partner with MoloLamken. (Photo: Diego M. Radzinschi/ALM) With Billions at Stake, Supreme Court Dips Its Toes Into Biologic Drug Patents
The justices have asked for the solicitor general's views on a cert petition by Amgen in a case that could reinterpret patent law's Section 112 and the law of enablement.
April 18, 2022 at 12:19 PM
5 minute read
Intellectual Property
The original version of this story was published on National Law Journal
The U.S. Supreme Court is showing some preliminary interest in reviewing biologic drug patents and the proper way to claim them, an issue potentially worth many billions of dollars.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
